trans-1,2-dihydro-1,2-naphthalenediol has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogh, A; Bödör, C; Karvaly, GB; Köllő, Z; Vásárhelyi, B; Vincze, I | 1 |
| Allal, B; Chatelut, E; De Barros, S; Despas, F; Dupré, L; Gallais, F; Obéric, L; Protin, C; Quillet-Mary, A; Thomas, F; White-Koning, M; Ysebaert, L | 1 |
2 other study(ies) available for trans-1,2-dihydro-1,2-naphthalenediol and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.
Topics: Adenine; Humans; Laboratories, Clinical; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Topics: Adenine; Adult; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Naphthalenes; Piperidines | 2020 |